simoctocog alfa

Simoctocog alfa is a fourth-generation recombinant antihemophilic factor (recombinant human coagulation factor VIII) used for the treatment and prophylaxis of bleeding in adults and children with hemophilia A (congenital factor VIII deficiency). It is produced using genetically modified human embryonic kidney (HEK) 293F cells via recombinant DNA technology, resulting in a B-domain deleted (BDD) form of FVIII that closely mimics endogenous human FVIII in its post-translational modifications. Simoctocog alfa acts as a replacement therapy to restore normal levels of factor VIII, thereby enabling effective blood clot formation and control or prevention of bleeding episodes. It is indicated for on-demand treatment, routine prophylaxis, and perioperative management of bleeding in patients with hemophilia A but is not indicated for von Willebrand disease. The drug was developed and is manufactured by Octapharma.

Brand names

Nuwiq

Other names

antihemophilic factor recombinanthuman coagulation factor VIII recombinantB-domain deleted recombinant FVIII